SCHEMBL28637610

SCHEMBL28637610

CNC(=O)c1cc2c(Oc3ccc(NC(=O)C4(C(N)=O)CC4c4ccc(F)cc4)cc3)ccnc2cc1OC

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 18/20 0.74
▸ MET P08581 8/20 0.70
▸ MERTK Q12866 5/20 0.62
▸ AURKA O14965 1/20 0.61
▸ RIPK2 O43353 1/20 0.61
▸ ABCB11 O95342 1/20 0.61
▸ ABL1 P00519 1/20 0.61
▸ EGFR P00533 1/20 0.61
▸ ERBB2 P04626 1/20 0.61
▸ NTRK1 P04629 1/20 0.61
▸ LCK P06239 1/20 0.61
▸ PGR P06401 1/20 0.61
▸ LYN P07948 1/20 0.61
▸ RET P07949 1/20 0.61
▸ CHRM2 P08172 1/20 0.61
▸ HCK P08631 1/20 0.61
▸ ADRA2A P08913 1/20 0.61
▸ ADORA3 P0DMS8 1/20 0.61
▸ KIT P10721 1/20 0.61
▸ CHRM1 P11229 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29995716 0.93 AXL (0.72) AXLMETMERTKAURKARIPK2
SCHEMBL12807168 0.92 MET (0.70) AXLMETMERTKAURKARIPK2
SCHEMBL29972991 0.92 MET (0.70) AXLMETMERTKAURKARIPK2
SCHEMBL1742894 0.92 MET (0.70) AXLMETMERTKAURKARIPK2
Zanzalintinib SCHEMBL29378531 0.85 AXL (1.00) AXLMETMERTKAURKARIPK2
Zanzalintinib SCHEMBL21200856 0.85 AXL (1.00) AXLMETMERTKAURKARIPK2
Malic Acid SCHEMBL29621016 0.84 MET (0.74) AXLMETMERTKAURKARIPK2
SCHEMBL21201281 0.83 AXL (1.00) AXLMETMERTKAURKARIPK2
SCHEMBL29995530 0.83 AXL (0.65) AXLMETMERTKAURKARIPK2
SCHEMBL30616292 0.83 AXL (0.59) AXLMETMERTKAURKARIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118647603-A Crystalline forms and salt forms of kinase inhibitors 埃克塞里艾克西斯公司 2024-09-13 — — CN disclosed
CN-113939503-B Crystalline salt forms of kinase inhibitors 埃克塞里艾克西斯公司 2024-05-07 — — CN disclosed
EP-4240333-A1 PHARMACEUTICAL COMPOSITIONS OF A KINASE INHIBITOR Exelixis, Inc. (US) 2023-09-13 — — EP disclosed
CN-116406261-A Pharmaceutical compositions of kinase inhibitors 埃克塞里艾克西斯公司 2023-07-07 — — CN disclosed
WO-2022098828-A1 PHARMACEUTICAL COMPOSITIONS OF A KINASE INHIBITOR EXELIXIS, INC. (US) 2022-05-12 — — WO disclosed
CN-113939503-A Crystalline salt forms of a kinase inhibitor 埃克塞里艾克西斯公司 2022-01-14 — — CN disclosed
CN-113329790-A Crystalline and salt forms of a kinase inhibitor 埃克塞里艾克西斯公司 2021-08-31 — — CN disclosed
Send feedback